These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 25978485)

  • 1. HIV, HCV, and Health-Related Harms Among Women Who Inject Drugs: Implications for Prevention and Treatment.
    Iversen J; Page K; Madden A; Maher L
    J Acquir Immune Defic Syndr; 2015 Jun; 69 Suppl 2(0 1):S176-81. PubMed ID: 25978485
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Women and barriers to harm reduction services: a literature review and initial findings from a qualitative study in Barcelona, Spain.
    Shirley-Beavan S; Roig A; Burke-Shyne N; Daniels C; Csak R
    Harm Reduct J; 2020 Oct; 17(1):78. PubMed ID: 33076931
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug Treatment as HIV Prevention Among Women and Girls Who Inject Drugs From a Global Perspective: Progress, Gaps, and Future Directions.
    Springer SA; Larney S; Alam-Mehrjerdi Z; Altice FL; Metzger D; Shoptaw S
    J Acquir Immune Defic Syndr; 2015 Jun; 69 Suppl 2(0 1):S155-61. PubMed ID: 25978482
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic review.
    Degenhardt L; Peacock A; Colledge S; Leung J; Grebely J; Vickerman P; Stone J; Cunningham EB; Trickey A; Dumchev K; Lynskey M; Griffiths P; Mattick RP; Hickman M; Larney S
    Lancet Glob Health; 2017 Dec; 5(12):e1192-e1207. PubMed ID: 29074409
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Women Who Use or Inject Drugs: An Action Agenda for Women-Specific, Multilevel, and Combination HIV Prevention and Research.
    El-Bassel N; Strathdee SA
    J Acquir Immune Defic Syndr; 2015 Jun; 69 Suppl 2(Suppl 2):S182-90. PubMed ID: 25978486
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Generating trust: Programmatic strategies to reach women who inject drugs with harm reduction services in Dar es Salaam, Tanzania.
    Zamudio-Haas S; Mahenge B; Saleem H; Mbwambo J; Lambdin BH
    Int J Drug Policy; 2016 Apr; 30():43-51. PubMed ID: 26880500
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A qualitative study of facilitators and barriers to participate in a needle exchange program for women who inject drugs.
    Värmå Falk M; Strömdahl S; Ekström AM; Kåberg M; Karlsson N; Dahlborn H; Hammarberg A
    Harm Reduct J; 2020 Oct; 17(1):84. PubMed ID: 33092595
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HIV and Hepatitis C Virus Infection and Risk Behaviors Among Heterosexual, Bisexual, and Lesbian Women Who Inject Drugs in Australia.
    Iversen J; Dolan K; Ezard N; Maher L
    LGBT Health; 2015 Jun; 2(2):127-34. PubMed ID: 26790118
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A prospective cohort study of risk behaviours, retention and loss to follow-up over 5 years among women and men in a needle exchange program in Stockholm, Sweden.
    Karlsson N; Kåberg M; Berglund T; Hammarberg A; Widman L; Ekström AM
    Int J Drug Policy; 2021 Apr; 90():103059. PubMed ID: 33360734
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatitis B, hepatitis C and HIV prevalence and related sexual and substance use risk practices among key populations who access HIV prevention, treatment and related services in South Africa: findings from a seven-city cross-sectional survey (2017).
    Scheibe A; Young K; Versfeld A; Spearman CW; Sonderup MW; Prabdial-Sing N; Puren A; Hausler H
    BMC Infect Dis; 2020 Sep; 20(1):655. PubMed ID: 32894072
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epidemiology of injecting drug use, prevalence of injecting-related harm, and exposure to behavioural and environmental risks among people who inject drugs: a systematic review.
    Degenhardt L; Webb P; Colledge-Frisby S; Ireland J; Wheeler A; Ottaviano S; Willing A; Kairouz A; Cunningham EB; Hajarizadeh B; Leung J; Tran LT; Price O; Peacock A; Vickerman P; Farrell M; Dore GJ; Hickman M; Grebely J
    Lancet Glob Health; 2023 May; 11(5):e659-e672. PubMed ID: 36996857
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Developing integrated community-based HIV prevention, harm reduction, and sexual and reproductive health services for women who inject drugs.
    Ayon S; Jeneby F; Hamid F; Badhrus A; Abdulrahman T; Mburu G
    Reprod Health; 2019 May; 16(Suppl 1):59. PubMed ID: 31138238
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Global Meta-analysis of the Prevalence of HIV, Hepatitis C Virus, and Hepatitis B Virus Among People Who Inject Drugs-Do Gender-Based Differences Vary by Country-Level Indicators?
    Leung J; Peacock A; Colledge S; Grebely J; Cunningham EB; Hickman M; Vickerman P; Stone J; Trickey A; Dumchev K; Lynskey M; Hines L; Griffiths P; Mattick RP; Degenhardt L; Larney S
    J Infect Dis; 2019 Jun; 220(1):78-90. PubMed ID: 30726973
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tales of gender-based oppression and violence: Risks and vulnerabilities of women who inject drugs (WWID) in Dhaka, Bangladesh.
    Irfan SD; Khan MNM; Khan SI
    Int J Drug Policy; 2021 Jun; 92():103144. PubMed ID: 33549468
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Elimination of HCV as a public health concern among people who inject drugs by 2030 - What will it take to get there?
    Grebely J; Dore GJ; Morin S; Rockstroh JK; Klein MB
    J Int AIDS Soc; 2017 Jul; 20(1):22146. PubMed ID: 28782335
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biomedical HIV Prevention Including Pre-exposure Prophylaxis and Opiate Agonist Therapy for Women Who Inject Drugs: State of Research and Future Directions.
    Page K; Tsui J; Maher L; Choopanya K; Vanichseni S; Mock PA; Celum C; Martin M
    J Acquir Immune Defic Syndr; 2015 Jun; 69 Suppl 2(0 1):S169-75. PubMed ID: 25978484
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Barriers and facilitators of access to HIV, harm reduction and sexual and reproductive health services by women who inject drugs: role of community-based outreach and drop-in centers.
    Ayon S; Ndimbii J; Jeneby F; Abdulrahman T; Mlewa O; Wang B; Ragi A; Mburu G
    AIDS Care; 2018 Apr; 30(4):480-487. PubMed ID: 29067855
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HIV Reduction Among Women Who Inject Drugs Can Be Achieved Through Women-Specific Programs and Global Targets: A Model From Ukraine.
    Deshko T
    J Acquir Immune Defic Syndr; 2015 Jun; 69 Suppl 2():S98-9. PubMed ID: 25978490
    [No Abstract]   [Full Text] [Related]  

  • 19. Integrating HCV testing with HIV programs improves hepatitis C outcomes in people who inject drugs: A cluster-randomized trial.
    Solomon SS; Quinn TC; Solomon S; McFall AM; Srikrishnan AK; Verma V; Kumar MS; Laeyendecker O; Celentano DD; Iqbal SH; Anand S; Vasudevan CK; Saravanan S; Thomas DL; Sachdeva KS; Lucas GM; Mehta SH
    J Hepatol; 2020 Jan; 72(1):67-74. PubMed ID: 31604081
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Global, regional, and country-level coverage of interventions to prevent and manage HIV and hepatitis C among people who inject drugs: a systematic review.
    Larney S; Peacock A; Leung J; Colledge S; Hickman M; Vickerman P; Grebely J; Dumchev KV; Griffiths P; Hines L; Cunningham EB; Mattick RP; Lynskey M; Marsden J; Strang J; Degenhardt L
    Lancet Glob Health; 2017 Dec; 5(12):e1208-e1220. PubMed ID: 29074410
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.